Navigation Links
AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
Date:10/31/2007

RESEARCH TRIANGLE PARK, N.C., Oct. 31 /PRNewswire/ -- AlphaVax, Inc. announced today that it has concluded a phase 1 clinical trial in 216 volunteers of an influenza vaccine based on its proprietary replicon vector platform. This study was designed to further assess the properties of this unique vector system as well as the feasibility of its application to influenza vaccines.

The study was a placebo-controlled, randomized, double-blind trial in healthy adults, 18-40 years old, which evaluated the safety and humoral and cellular immune responses after one or two inoculations. The replicon vector expressed the hemagglutinin (HA) gene derived from the A/Wyoming (H3N2) strain of influenza virus. The vaccine was administered either subcutaneously or intramuscularly at two dosage levels, and was found to be safe and well tolerated irrespective of the route or the dose given.

Both antibody and T cell responses were efficiently stimulated and persisted for the duration of the four-month study. Among volunteers with prevaccination influenza antibody titers (measured by hemagglutination inhibition, or "HI") that were below levels thought to be protective, 77% and 80% of these individuals receiving a single low or high dose, respectively, responded with protective HI antibody titers. A second immunization in these individuals increased seroprotective responses to 86% for both dosage levels. A rapid and dose-dependent T cell response (defined in antigen-specific IFN-gamma ELISPOT assays) was also observed and remained significantly elevated for at least four months. A second immunization extended the duration, but not the magnitude of these T cell responses. For both antibody and cellular responses, there was no significant difference observed between subcutaneous and intramuscular vaccinations.

"We were pleased to see the balanced immune response consisting of both humoral and cellular responses", said Dr. Jonathan Smith, CSO at AlphaVax. "Comparable
'/>"/>

SOURCE AlphaVax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
... 17, 2011 Stryker Corporation,s Orthopaedics Division and ... announced an agreement in which OrthoSensor will provide ... Stryker,s Triathlon Knee System. The OrthoSensor Knee Trial ... feedback to surgeons to optimize joint balance during ...
... 2011  ConvaTec, a world-leading developer and marketer of ... announced the appointments of Charles Cerminara and James Moran ... been appointed Vice President and General Manager, Greater China, ... the growth of the Chinese market and to leverage ...
Cached Medicine Technology:Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform 2Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform 3ConvaTec Announces Asia-Pacific Leadership Appointments 2
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 (HealthDay ... are more likely to get a pacemaker than people without ... of more than 16,000 people found that those with dementia ... pacemaker than those without the memory-robbing condition. What ... are so much more likely to be treated with a ...
(Date:7/28/2014)... Michigan (PRWEB) July 28, 2014 The ... Drs. Harris, Birkhill, Wang, Songe and Associates, PC that ... and countless tomorrows to come. , The HBWS ... responsible for more than $2.5 million in donations. Through ... title sponsors for the Oakwood Women’s Healthcare Classic for ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... apnea in children, but a new study confirms that the ... already overweight. The researchers said that,s a concern, because ... problems -- including, ironically, sleep apnea. But they,re not advising ... said, doctors and parents should be aware that a healthy ...
(Date:7/28/2014)... 28, 2014 Lourdes Health System has ... and reduced wait times for veterans needing medical care. ... in the state—and the only one in Camden, Burlington ... Community Care program (PC3). PC3 gives veterans access to ... cannot provide services due to lack of available specialists, ...
(Date:7/28/2014)... 28, 2014 The American ... of professionals engaged in the field of organ ... Transplantation and Immunology Research Network (TIRN), a ... research. As modern organ transplantation continues to diversify, ... could provide more opportunities for physicians, scientists and ...
Breaking Medicine News(10 mins):Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3
... Neb., March 1 Nelnet, Inc. (NYSE: ... of its 2008 year-end results,as the company,s independent external ... derivative portfolio, which is excluded from base,net income. The ... market open on March 2, 2009. Depending on the ...
... the security alarms of the immune system. After sensing ... alarm to white blood cells or tell them to ... , Researchers at the Emory Vaccine Center and Yerkes ... can respond to the same compound, through two different ...
... office in Tokyo. , ... (PRWEB) March 1, 2009 ... services firm, which provides clinical research support services to pharmaceutical, biotechnology, ... Tokyo, Japan., , ,To meet the growing needs and serve its ...
... Ill. A study in the March 1 issue of ... intrinsic sleep problem specific to attention-deficit/hyperactivity disorder (ADHD) and supports ... deprived and have abnormal REM sleep. , Results ... that is significantly shorter than that of controls. Children ...
... Brian Schweitzer (Chair of the Democratic Governors Association) and ... today applauded President Obama,s reported selection of former DGA ... Human Services. "Our health care system is broken, and ... the effort to fix it," Governor Schweitzer said. "In ...
... for rare, orphan and neglected diseases, launches iWish, which allows people ... these diseases through and image. In addition, people are invited to ... creative solutions for a rare disease or for the community in ... ...
Cached Medicine News:Health News:Vitamin A signals offer clues to treating autoimmunity 2Health News:Underlying sleep problem linked to attention-deficit/hyperactivity disorder in children 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 3
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
The larger volume alternative to the ART Gel 20P, this gel loading tip can load up to 100 L....
Medicine Products: